David Meek

David Meek is a seasoned executive in the biotechnology sector, currently known for his role as Chief Executive Officer at Mirati Therapeutics, a position he held from September 2021 until August 2023. He has extensive experience in leadership roles within the pharmaceutical industry, having served in various capacities at notable companies.

Professional Background

• Current Role: Chief Executive Officer at Mirati Therapeutics (September 2021 - August 2023).
• Previous Positions:
  • Chief Executive Officer at FerGene (January 2020 - July 2021).
  • Chief Executive Officer at Ipsen (July 2016 - January 2020).
  • Executive Vice President & President of Oncology at Baxalta (July 2014 - July 2016).
  • Chief Commercial Officer at Endocyte (August 2012 - July 2014).

Meek has also held significant roles at Novartis, where he was the Region Head for Oncology and CEO & President of Novartis Canada, among other positions. His career began at Janssen Pharmaceuticals, where he spent over 15 years in various marketing and sales roles.

Education

David Meek holds a Bachelor of Arts (B.A.) degree from the University of Cincinnati.

Current Affiliations

In addition to his work at Mirati Therapeutics, Meek is a member of the board of directors for uniQure, a gene therapy company, indicating his ongoing influence and commitment to advancing biotechnology and therapeutic innovations.1